- Home
- LOGC vs PLX Comparison
LOGC vs PLX Comparison
Compare LOGC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- PLX
- Stock Information
- Founded
- LOGC 2010
- PLX 1993
- Country
- LOGC United States
- PLX Israel
- Employees
- LOGC N/A
- PLX N/A
- Industry
- LOGC Catalog/Specialty Distribution
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOGC Consumer Discretionary
- PLX Health Care
- Exchange
- LOGC Nasdaq
- PLX Nasdaq
- Market Cap
- LOGC 175.8M
- PLX 160.2M
- IPO Year
- LOGC 2020
- PLX 1998
- Fundamental
- Price
- LOGC $6.74
- PLX $2.33
- Analyst Decision
- LOGC
- PLX
- Analyst Count
- LOGC 0
- PLX 0
- Target Price
- LOGC N/A
- PLX N/A
- AVG Volume (30 Days)
- LOGC 208.4K
- PLX 553.9K
- Earning Date
- LOGC 03-03-2025
- PLX 03-13-2025
- Dividend Yield
- LOGC N/A
- PLX N/A
- EPS Growth
- LOGC N/A
- PLX N/A
- EPS
- LOGC N/A
- PLX N/A
- Revenue
- LOGC $96,000,000.00
- PLX $45,667,000.00
- Revenue This Year
- LOGC N/A
- PLX N/A
- Revenue Next Year
- LOGC $422.91
- PLX $90.00
- P/E Ratio
- LOGC N/A
- PLX N/A
- Revenue Growth
- LOGC N/A
- PLX N/A
- 52 Week Low
- LOGC $4.13
- PLX $0.82
- 52 Week High
- LOGC $8.24
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- LOGC 45.97
- PLX 78.72
- Support Level
- LOGC $6.29
- PLX $2.11
- Resistance Level
- LOGC $6.97
- PLX $2.36
- Average True Range (ATR)
- LOGC 0.31
- PLX 0.12
- MACD
- LOGC -0.02
- PLX 0.00
- Stochastic Oscillator
- LOGC 40.00
- PLX 94.23
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.